Omni Partners US’s The Oncology Institute TOI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
$7.65M Buy
769,766
+700,667
+1,014% +$6.96M 0.39% 43
2021
Q2
$688K Buy
+69,099
New +$696K 0.03% 191

Other funds holding TOI

Omni Partners US's TOI Position: Q3 2021 in Review

Omni Partners US increased its The Oncology Institute (TOI) stake by 1,014% in Q3 2021, buying an estimated $6.96M and bringing the position to 769,766 shares worth $7.65M. The position accounts for 0.39% of the portfolio, ranked #43.

Omni Partners US first reported a position in TOI in Q2 2021 and has held it in 2 quarters since. 51 funds tracked by Wall St. Rank hold TOI as of Q3 2021.

  • Omni Partners US held 769,766 shares of The Oncology Institute worth $7.65M as of Q3 2021.
  • Omni Partners US bought 700,667 The Oncology Institute shares in Q3 2021, an estimated $6.96M.
  • The Oncology Institute made up 0.39% of Omni Partners US's portfolio in Q3 2021, its #43 holding.
  • Omni Partners US first reported a position in The Oncology Institute in Q2 2021 and has held it in 2 quarters since.
  • 51 funds tracked by Wall St. Rank held The Oncology Institute as of Q3 2021.

Based on Omni Partners US's 13F filing for Q3 2021, filed 15 Nov 2021.